Biologic Mesh Reconstruction of the Pelvic Floor after Extralevator Abdominoperineal Excision: A Systematic Review

Nasra N. Alam1, Sunil K. Narang1, Ferdinand Köckerling2, Ian R. Daniels1 and Neil J. Smart1*

1 Exeter Surgical Health Services Research Unit (HeSRU), Royal Devon and Exeter Hospital, Exeter, Devon, UK, 2 Department of Surgery, Center for Minimally Invasive Surgery, Academic Teaching Hospital of Charité Medical School, Vivantes Hospital, Berlin, Germany

Introduction: The aim of this review is to provide an overview of the evidence for the use of biologic mesh in the reconstruction of the pelvic floor after extralevator abdominoperineal excision of the rectum (ELAPE).

Methods: A systematic search of PubMed was conducted using the search terms: “ELAPE,” “extralevator abdominoperineal excision of rectum,” or “extralevator abdominoperineal resection.” The search yielded 17 studies.

Results: Biologic mesh was used in perineal reconstruction in 463 cases. There were 41 perineal hernias reported but rates were not consistently reported in all studies. The most common complications were perineal wound infection (n = 93), perineal sinus and fistulae (n = 26), and perineal haematoma or seroma (n = 11). There were very few comparative studies, with only one randomized control trial (RCT) identified that compared patients undergoing ELAPE with perineal reconstruction using a biological mesh, with patients undergoing a conventional abdominoperineal excision of the rectum with no mesh. There was no significant difference in perineal hernia rates or perineal wound infections between the groups. Other comparative studies comparing the use of biologic mesh with techniques, such as the use of myocutaneous flaps, were of low quality.

Conclusion: Biologic mesh-assisted perineal reconstruction is a promising technique to improve wound healing and has comparable complications rates to other techniques. However, there is not enough evidence to support its use in all patients who have undergone ELAPE. Results from high-quality prospective RCTs and national/international collaborative audits are required.

Keywords: ELAPE, extralevator abdominoperineal excision of rectum, extralevator abdominoperineal resection, pelvic floor reconstruction, biological mesh
INTRODUCTION

Abdominoperineal excision of the rectum (APER) is used as a treatment modality in patients with rectal cancer where an anterior resection (AR) and an anastomosis cannot be performed (1). Extralevator abdominoperineal excision (ELAPE) involves the en bloc excision of the levator muscles and the rectum, in order to reduce the risk of tumor involvement in the circumferential resection margins (CRMs) and reduce the risk of tumor perforation intraoperatively. This method has been demonstrated as leading to a wider surgical margin and therefore fewer positive CRMs (2–5). Initially, the terminology used was “cylindrical APER” but with refinement and the use of MRI to highlight the area of risk of a positive CRM, the term ELAPE is more appropriate (4). The nomenclature surrounding the technique has been the source of much debate and confusion, with some authors noting that ELAPE is no different from the original description in English by Miles (6). Furthermore, what exactly constitutes “standard” surgery that allows differentiation of ELAPE has come under scrutiny (7).

Volumetric analysis has confirmed that ELAPE does remove more tissue (3), and the wider excision can, however, increase morbidity and wound complications and will require some form of perineal reconstruction (4). Perineal wound problems are reported in up to 57% of patients undergoing APER (8), although the precise rates following ELAPE are not yet known. Given that ELAPE produces a larger defect in the pelvic floor, leaving only the ischiorectal fat and skin to close the perineal wound; it is presumed that the perineal complication rate is higher. Furthermore, the changes in the proportion of patients having neoadjuvant (chemo)radiotherapy over the time course of ELAPE implementation are incompletely reported in individual studies and in national registries. If the wound fails to heal via primary intention, secondary wound healing can result in prolonged hospital stay that requires intensive wound care.

Various alternative techniques have been described to reconstruct the pelvic floor following ELAPE with the aim to reduce perineal wound complications and hernias. The optimal method of perineal reconstruction remains a matter of debate. Myocutaneous flaps, such as those derived from glutaeus maximus (2, 4, 9), rectus abdominis, and latissimus dorsi muscles (4, 10), have been used but are associated with donor-site morbidity, flap necrosis, prolonged operative time, additional resources, and increased cost. Biologic mesh has recently been introduced as an alternative form of reconstruction in order to improve perineal wound healing and reduce perineal hernia rates (11). The mesh is usually placed as an inlay or bridge across the defect in the pelvic floor in close relation to the bony structures and sutured in 1-cm intervals to the origin of thelevator muscles laterally (12). [Figure 1 (13)] The mechanism by which the use of a bridging prosthesis reduces perineal wound problems is not clear. It has been suggested that biological mesh allows native cellular ingrowth and promotes tissue remodeling, which in turn reduces perineal wound problems (14, 15). Alternatively, the biologic mesh may act as a physical barrier, supporting the pelvic contents (omentum, small bowel, and uterus) and minimizing the pressure on the skin and ischiorectal fat as they heal.

Alternative methods for removing the pressure of small bowel that prolapses into the pelvis, directly on the perineum include the following:

1. Omental pedicle flaps (16–18),
2. Mobilization of the cecum (9),
3. Retroversion of the uterus in female (19).

All of the above techniques are designed to close off the dead space in the pelvis, resulting from the removal of the rectum and to keep the small bowel out of the pelvis. Of these methods, the most widely established is the omental pedicle. However, these techniques largely related to an era of open surgery, and they have mostly been abandoned with the move to laparoscopic and other minimally invasive techniques and are not representative of contemporary practice. Omental pedicles are associated with perineal wound complication rates of 14–18% and decreased wound dehiscence in comparison to primary closure (16, 18) whereas others show no advantage to this technique (20). Mobilization of the cecum is uncommon and evidence is limited to case reports (9). Retroversion of the uterus involves retroverting the uterus and securing it to the bony pelvis at a level where it obliterates the pelvis, with the use of non-absorbable suture material (19). This can be achieved via the abdominal or perineal wound, although it has been associated with dyspareunia and positional menstruation (19).

The aim of this review is to provide an overview of the evidence for the use of biologic mesh in the reconstruction of the pelvic floor after extralevator abdominoperineal excision.

METHODS

A systematic search of PubMed was conducted using the search terms: “ELAPE,” “extralevator abdominoperineal excision of rectum,” or “extralevator abdominoperineal resection” in order to
identify studies evaluating the use of biologic mesh for reconstruction of the pelvic floor. Titles, abstracts, and full texts were analyzed for studies reporting on the use of biologic mesh for reconstruction of the pelvic floor. Inclusion criteria were studies that used biologic mesh for perineal reconstruction. Studies were excluded if only synthetic mesh was used or if there was no mention of a mesh. Furthermore, studies on patients under the age of 18 were excluded as well as non-English language studies, technical tips, conference abstracts, or duplicates series from the same research group. Overall, the search yielded 17 studies for analysis after the exclusion of review articles. The study characteristics are presented (Table 1).

RESULTS

There were 15 case series, one randomized control trial (RCT), and one case report identified. A biologic mesh was used in perineal reconstruction in 463 cases. The different types of biologic mesh used were cross-linked porcine dermal collagen (Permacol™) in 206 cases, 44 using porcine intestinal submucosa (Surgisis®), 136 using human acellular dermal matrix, and 9 using a combination of Permacol™ and Surgisis®. Two studies did not specify the type of biologic mesh used.

Perineal Hernia

There were 41 perineal hernias reported, but rates were not consistently reported in all studies. In those studies that did report perineal hernia rates, it was difficult to delineate whether hernias occurred in patients that had perineal reconstruction using a biological or synthetic mesh or a myocutaneous flap.

Perineal Wound Infection/Healing Problems

Perineal wound infection was reported explicitly in 93 cases, whereas the overall rate of perineal problems was much higher. Perineal sinus and fistulae were reported in 26 cases, with a further 11 cases of perineal hematoma or seroma. Some studies have described “perineal wound complications” but not specified whether they were related to infection, dehiscence, hernia, or pain (Table 1).

The most common complications were perineal wound infection and perineal sinus. However, there are no standardized measures for reporting perineal outcomes of any type following ELAPE. Definitions of wound infection, wound healing problems, perineal herniation, pain measurement, and functional status assessment are inconsistent between studies, thus limiting comparisons.

There are very few studies comparing the use of biologic mesh for perineal reconstruction for ELAPE. Two case series compared biologic mesh with myocutaneous flaps and one series compared laparoscopic ELAPE with laparoscopic and open APER. However, they are all of low-level evidence (level 4). Only one RCT was identified that compared patients undergoing ELAPE with perineal reconstruction using a biological mesh, with patients undergoing a conventional APER with no mesh. There was no significant difference in perineal hernia rates or perineal wound infections between the two groups.

DISCUSSION/SUMMARY

The use of ELAPE over conventional APER is becoming more widespread despite the reservations of some (13), and the optimal method of perineal wound closure remains a topic of discussion. The reported results of primary closure of the perineal defect are poor (34) and most surgeons performing ELAPE opt for an adjunct (35). The literature analyzed suggests that perineal closure using a biologic mesh produces wound infection and complication rates that are comparable to other methods of reconstruction, such as myocutaneous flaps. Myocutaneous flap reconstruction using a vertical rectus abdominis (VRAM), gracilis, or the gluteus maximus, however, has short-term disadvantages, such as longer operative times and the need for plastic surgical expertise, resulting in higher operative costs, flap necrosis, wound complications at the donor site, and longer bed rest (15). Longer term incisional hernias at the VRAM donor site and reduced abdominal wall strength have been reported (36). Biologic mesh reconstruction avoids all of these potential complications.

Synthetic non-absorbable mesh is associated with high infection rate in contaminated fields and consequently is considered by many to be contra-indicated for use in perineal reconstruction following ELAPE (37). The role of newer, absorbable synthetic meshes is, as yet, unclear. Biologic meshes are composed of an acellular collagen matrix that is believed to allow tissue regeneration, neovascularization, repopulation with fibroblasts, and therefore provides a scaffold for tissue incorporation (15, 23). This is thought to reduce the rate of infection. However, the overall volume and quality of evidence available regarding biologic mesh use for perineal reconstruction following ELAPE is poor, with observational retrospective studies predominating. There have been some attempts at comparative studies, but these too have been of low quality with a high risk of bias and confounding factors. Head-to-head randomized trials or high-quality prospective cohort studies comparing biological with synthetic mesh, types of biologic mesh, and biologic mesh with (myo)fasciocutaneous flaps are also lacking, partly because there is no consensus among surgeons as to the optimal biologic mesh or optimal tissue flap. Trials directly comparing any technical adjunct to primary closure alone as a control arm may be difficult to perform in light of the lack of equipoise among surgeons and possibly even unethical given the reported poor results of primary closure. Furthermore, there does not appear to be a consensus in the studies regarding perineal outcome reporting. There are a variety of different end points recorded across the studies, such as perineal defect size, blood loss, and operating time. There needs to be a focus on standardized definitions and reporting of perineal healing rates, perineal hernia, and functional outcomes following ELAPE (38).

Jensen et al. also examined the long-term follow-up for patients undergoing pelvic floor reconstruction with a biologic mesh following ELAPE (25). As well as low perineal hernia rates, there was no major restriction in movement or sitting. Chronic pain had resolved in all patients at a median of 8 months, and there was no major limitation to walking. However, other studies evaluating quality-of-life scores using validated tools (11) demonstrated a favorable comparison to the reference population of patients with colorectal cancer who had undergone a standard
| Reference | Study design | No. of pts | Age | Sex (M:F) | Patient characteristics | Material used | Intervention | Follow-up (months) | Complications | LoE |
|-----------|--------------|------------|-----|-----------|-------------------------|---------------|--------------|-------------------|---------------|-----|
| Christensen et al. (21) | Case series | 57 | FLAP: 67.8 (32.7–86.6) | 11:22 | 52 primary rectal cancer 5 local recurrence 48 patients (84%) | Gluteal flaps: 33 | ELAPE for low rectal cancer | Median follow-up: gluteal flap: 3.2 years (1.7–4.3) Biologic mesh: 1.7 (0.4–2.2) years | Perineal hernia: 7 vs. 0, P < 0.01 Infectious complications: 2 (17%) vs. 4 (6%), P < 0.26 1 patient per group with a persistent perineal sinus | 4 |
| Dalto et al. (22) | Case series | 31 | Mean 66.8 ± SD 11.4 years | 8:23 | Neoadjuvant CRT: 14 | VRAM flap: 1 Permacol: 30 | Open ELAPE | Median: 20 (0–45) | Breakdown of perineal wound: 6 Skin paddle necrosis of a VRAM flap: 1 Perineal wound hematoma: 1 Minor wound discharge: 9 | 4 |
| Han et al. (23) | Case series | 12 | 68 (49–80) | 7:5 | Ultra low rectal cancer. Neoadjuvant CRT: 3 | HADM | Cylindrical APR-open | Median: 8 (2–16) | Asymptomatic seroma: 1 Perineal wound infection: 1 | 4 |
| Han et al. (14) | Open label RCT | 67 | 63 median (44–81) | 20:15 | Neoadjuvant therapy: 10 | HADM | ELAPE: 35 | Median: 29 (12–48) | Bowel perforation: 2 Perineal wound infection: 4 Perineal seroma: 4 Peristomal hernia: 16 Abdominal wound infection: 2 Perineal herniation: 5 Bowel perforation: 5 Perineal wound infection: 6 Peristomal hernia: 13 Abdominal wound infection: 3 Perineal herniation: 4 | 2 |
| Han et al. (24) | Multicenter prospective cohort study (case series) | 109 (102) | 61 years (27–78) | 60:42 | HADM | Biological mesh: 83 (81.4%) Primary closure: 19 (18.6%) | Biological mesh Perineal wound complications: 15 Infection: 5 Seroma: 5 Hernia: 4 Abdominal wound infection: 3 Primary closure Perineal wound complications: 9 Infection: 3 Seroma: 1 Hernia: 2 Wound dehiscence: 3 Chronic sinus: 1 Abdominal wound infection: 2 | 4 |

(Continued)
| Reference          | Study design | No. of pts | Age       | Sex (M:F) | Patient characteristics | Material used | Intervention | Follow-up (months) | Complications                                      | LoE |
|-------------------|--------------|------------|-----------|-----------|-------------------------|---------------|--------------|--------------------|----------------------------------------------------|-----|
| Jensen et al. (25) | Case series  | 53–31      | 69 (33–83) median | 33:20 | Neoadjuvant CRT: 23    | Permacol      | 6 planned open | Median: 36 (1–67) | Perineal hernia: 3 Fistula: 11 Perineal abscess: 4 Superficial wound infections: 4 Removal of mesh: 1 Implantation of new mesh: 1 | 4   |
| Kipling et al. (26) | Case series  | 28         | 70 (52–81 years) median | 20:8  | Neoadjuvant therapy None: 9 (32%) Short course: 2 (7%) Long course: 17 (61%) | Permacol      | Lap ELAPE, 5 conversions | Median 38 (23–66) | Bowel perforation: 1 Persistent perineal sinus at 6 months: 1 Delayed healing of the perineal wound: 1 | 4   |
| Peacock et al. (15) | Case series (comparative) | 15 | 68 median (48–74) | 4:1 | Long-course CT/RT: 4 Long-course RT: 1 Cylindrical APER | VRAM: 5 | Median: 29 (23–35) | Perineal wound infection (wound dehiscence): 1 Flap necrosis: 1 Wound hematoma: 1 Perineal sinus: 1 | 4   |
| Peacock et al. (27) | Case series  | 34         | Median 62 years (40–77) | 27:7  | Long-course CRT: 26 Long-course RT (not suitable for CT): 2 | Surgisis:    | Median: 21 (1–54) | Perineal sinus: 5 Superficial perineal wound infection: 3 Abscess/collection: 3 | 4   |
| Vaughan-Shaw et al. (28) | Case series (case-control) | 16 | 71 (49–88) | 7:9 | Short-course RT: 7 Long-course CRT: 9 9 Permacol/Surgisis | Laparoscopic ELAPE: 14 (1 conversion) Open: 2 | | Return to theater (<30 days): 2 Perineal wound complications: 2 Perineal wound infections: 5 Perineal hernia: 2 Infection: 1 Return to theater (<30 days): 1 In-hospital mortality: 1 Perineal wound complications: 2 | 4   |
| Wille-Jørgensen et al. (29) | Case series  | 11         | Median 63 median (51–77) | 7:4  | Neoadjuvant CRT: 6   | Permacol      | Laparoscopic APER: 9 (2 conversions) Open APER: 2 | Median: 12 (3–18) | Mesh removal 2nd to infection: 1 Rectal perforation: 1 Long-lasting perineal pain: 6 Fistula: 1 | 4   |
| Chi et al. (30)    | Case series  | 6          | Mean: 69 | 4:2 | Neoadjuvant CRT 4     | HADM          | Mean: 5 (2–19) | Surgical site infection: 2 | | 4   |
| Reference | Study design | No. of pts | Age (M:F) | Patient characteristics | Material used | Intervention | Follow-up (months) | Complications | LoE |
|-----------|--------------|------------|-----------|-------------------------|---------------|--------------|---------------------|---------------|-----|
| Palmer et al. (31) | Case series | 193 | 66 median (28–87) | 81:112 | Neoadjuvant CRT: 91 RT alone: 92 Locally advanced tumor on MRI (T4)-126 (65%) | Pelvic exenteration: 25, extended resection with parts of other organs: 56 ELAPE alone: 112 | Median 31 (0–156) | Intra-operative perforation: 19 30-day postoperative mortality: 6 | 4 |
| West et al. (4) | Retrospective case series (multicenter) | 176 | 66 (58–73) Median 6-unknown | 116:54 | Neoadjuvant RT Yes: 135 No: 35 Unknown: 11 Neoadjuvant CT Given: 84 Not given: 81 Unknown: 11 | ELAPE: 176 Open surgery: 122 Laparoscopic surgery: 19 Unknown: 35 | NS | Wound complications Yes: 57 Infection/breakdown/sinus: 41 Perineal hernia: 5 Other: 11 | 4 |
| | | 124 | 68 (57–75) median | 87:37 | Neoadjuvant RT Yes: 90 No: 24 Unknown: 10 Neoadjuvant CT Given: 48 Not given: 66 Unknown: 10 | APER: 124 Open surgery: 56 Laparoscopic surgery: 4 Unknown: 64 | NS | Wound complications Yes: 11 Infection/breakdown/sinus: 7 Perineal hernia: 1 Other: 3 Unknown: 26 | 4 |
| Harries et al. (32) | Prospective case series | 48 | Median: 63 (40–86) | 36:12 | Neoadjuvant treatment: 43 | ELAPE Lap: 28 Conversion: 7 Open: 23 | Median: 27 (1–85) | Specimen perforation: 3 (6.4%) Unhealed at 6 months: 4 (8.3%) Perineal sinus: 7 Abdominal wound dehiscence: 1 Ureteric injury: 1 Radiological drainage of pelvic collections: 2 Perineal wound infections: 9 | 4 |
| Kavanagh et al. (33) | Case report | 1 | 72 | 0:1 | Long-course CRT | Permacol Lap ELAPE | 12 | NS | | 4 |
| Sayers et al. (34) | Case series | 54 | Median: 69.5 (31–90) | 40:14 | Neoadjuvant CRT: 52 Primary closure: 46 Bio: 2 FLAP: 6 (VRAM: 5 Gracilis: 1) | Lap ELAPE: 20 Open: 34 | Median: 38 (9–61) | Perineal complications: 24 Perineal hernia: 14 Perineal hematoma: 1 Infected myocutaneous flap: 1 Total dehiscence of the perineum: 1 | 4 |

APER, abdominoperineal excision of the rectum; CRT, chemoradiotherapy; CT, chemotherapy; ELAPE, extralevator abdominoperineal excision; HADM, human acellular dermal matrix; LoE, level of evidence; RCT, randomized controlled trial; RT, radiotherapy; VRAM, vertical rectus abdominis muscle.
APE, whereas patients who had undergone flap reconstruction had a lower quality of life score (11).

Of note, a number of studies from Beijing have been included for analysis. The three studies include patients managed over an approximately 3-year period, and there is overlap of the studies within the time period, therefore suggesting some replication. One study is classified as a case series (23), the second a RCT (14), and the third another case series (24). It is unclear as to whether these three studies are from the same patient group or three different cohorts.

CONCLUSION

Overall, the use of a biologic mesh to close perineal defects has comparable complications rates to myocutaneous flaps but may offer advantages, such as shorter operating time and early mobilization, which results in a more cost-effective repair (15). Biologic mesh-assisted perineal reconstruction is a promising technique to improve wound healing, but there is not enough evidence to support its use in all patients who have undergone ELAPE. The results from high-quality prospective RCTs or national/international collaborative audits using statistical process control as a methodology of assessment of improvement are required.

AUTHOR CONTRIBUTIONS

All authors listed have made substantial, direct, and intellectual contribution to the work and approved it for publication.

REFERENCES

1. Perry WB, Connaughton JC. Abdominoperineal resection: how is it done and what are the results? J Clin Colorectal Surg (2007) 20(3):213–20. doi:10.1055/s-2007-984865
2. Holm T, Ljung A, Häggmark T, Jurell G, Lagergren J. Extended abdominoperineal resection with glutens maximus flap reconstruction of the pelvic floor for rectal cancer. Br J Surg (2007) 94(2):232–8. doi:10.1002/bjs.5489
3. West NP, Finan PJ, Anderin C, Lindholm J, Holm T, Quirke P. Evidence of the oncologic superiority of cylindrical abdominoperineal excision for low rectal cancer. J Clin Oncol (2008) 26(21):3517–22. doi:10.1200/JCO.2007.14.5961
4. West NP, Anderin C, Smith KJ, Holm T, Quirke P. European Extralevator Abdominoperineal Excision Study Group. Multicentre experience with extralevator abdominoperineal excision for low rectal cancer. Br J Surg (2010) 97(4):588–99. doi:10.1002/bjs.6916
5. Shihab OC, Heald RJ, Holm T, How PD, Brown G, Quirke P, et al. A pictorial description of extralevator abdominoperineal excision for low rectal cancer. Colorectal Dis (2012) 14(10):e655–60. doi:10.1111/j.1463-1318.2012.03181.x
6. Miles WE. A method of performing abdomino-perineal excision for carcinoma of the rectum and of the terminal portion of the pelvic colon (1908). CA Cancer J Clin (1971) 21(6):361–4. doi:10.3322/canjclin.21.6.361
7. Nicholls J. No more ‘standard’ abdominoperineal excision. Colorectal Dis (2003) 5(1):1329–30. doi:10.1111/cod.12458
8. de Bruin AF, Gosselink MP, Wijffels NA, Coene PP, van der Harst E. Local antibiotic: the answer to prevent perineal infection? Dis Colon Rectum (2008) 51(6):711–7. doi:10.1007/DCR.0b013e3182163c89
9. Dalton RS, Smart NJ, Edwards TJ, Chandler I, Daniels IR. Short-term outcomes of the prone perineal approach for extra-levator abdomino-perineal excision (ELAPE). Surgeon (2012) 10(6):342–6. doi:10.1111/j.1743-5861.2011.01001.x
10. Han JG, Wang ZJ, Gao ZG, Xu HM, Yang ZH, Jin ML. Pelvic floor reconstruction using human acellular dermal matrix after cylindrical abdominoperineal resection. Dis Colon Rectum (2010) 53(2):219–23. doi:10.1007/D01818-010-9185-3
11. Habib K. Prevention of recurrent small bowel obstruction resulting from pelvic adhesions in patients who have previously undergone abdominoperineal excision of the rectum. Tech Coloproctol (2014) 18(12):1179–80. doi:10.1007/s10151-014-1227-8
12. McNamara DE, Clements D, Edwards TJ, Fitton AR, Douie WJ. Biologic Mesh Reconstruction after ELAPE. The results from high-quality prospective RCTs or national/international collaborative audits using statistical process control as a methodology of assessment of improvement are required.
abdominoperineal excision (ELAPE) of the rectum versus conventional laparoscopic and open abdominoperineal excision: comparative analysis of short-term outcomes and quality of life. *Tech Coloproctol* (2012) **16**(5):355–62. doi:10.1007/s10151-012-0851-4

29. Wille-Jørgensen P, Pilsgaard B, Møller P. Reconstruction of the pelvic floor with a biological mesh after abdominoperineal excision for rectal cancer. *Int J Colorectal Dis* (2009) **24**(3):323–5. doi:10.1007/s00384-008-0607-9

30. Chi P, Chen ZF, Lin HM, Lu XR, Huang Y. Laparoscopic extralevator abdominoperineal resection for rectal carcinoma with transabdominal levator transection. *Ann Surg Oncol* (2013) **20**(5):1560–6. doi:10.1245/s10434-012-2675-x

31. Palmer G, Anderin C, Martling A, Holm T. Local control and survival after extralevator abdominoperineal excision for locally advanced or low rectal cancer. *Colorectal Dis* (2014) **16**(7):527–32. doi:10.1111/codi.12610

32. Harries RL, Luhmann A, Harris DA, Shami JA, Appleton BN. Prone extralevator abdominoperineal excision of the rectum with porcine collagen perineal reconstruction (Permacol™): high primary perineal wound healing rates. *Int J Colorectal Dis* (2014) **29**(9):1125–30. doi:10.1007/s00384-014-1963-2

33. Kavanagh DO, Imran H, Almoudaris A, Ziprin P, Faiz O. Dynamic magnetic resonance imaging demonstrates the integrity of perineal reconstruction following cylindrical abdominoperineal excision with reconstruction of the pelvic floor using porcine collagen. *Case Rep Med* (2012) **2012**:752357. doi:10.1155/2012/752357

34. Sayers AE, Patel RK, Hunter IA. Perineal hernia formation following extralevator abdominoperineal excision. *Colorectal Dis* (2015) **17**(4):351–5. doi:10.1111/codi.12843

35. Dabbas N, Adams K, Chave H, Branagan G. Current practice in abdominoperineal resection: an email survey of the membership of the Association of Coloproctology. *Ann R Coll Surg Engl* (2012) **94**(3):173–6. doi:10.1308/003588412X13171221589973

36. Daigeler A, Simidjiiska-Belyaeva M, Drücke D, Goertz O, Hirsch T, Soimaru C, et al. The versatility of the pedicled vertical rectus abdominis myocutaneous flap in oncologic patients. *Langenbecks Arch Surg* (2011) **396**(8):1271–9. doi:10.1007/s00423-011-0823-6

37. Choi JI, Palaniappa NC, Dallas KB, Rudich TB, Colon MJ, Divino CM. Use of mesh during ventral hernia repair in clean-contaminated and contaminated cases: outcomes of 33,832 cases. *Ann Surg* (2012) **255**(1):176–80. doi:10.1097/SLA.0b013e3182251866

38. Haapamäki MM, Pihlgren V, Lundberg O, Sandzén B, Rutegård J. Physical performance and quality of life after extended abdominoperineal excision of rectum and reconstruction of the pelvic floor with glutaeus maximus flap. *Dis Colon Rectum* (2011) **54**(1):101–6. doi:10.1007/DCR.0b013e31811f26e6

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2016 Alam, Narang, Köckerling, Daniels and Smart. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*